Page 106 - Drug Class Review
P. 106
Page 83 of 205
Drug Effectiveness Review Project
To compare efficacy and safety of TAC with placebo in patients with probable AD
placebo NA 12 weeks 158 Men and women with probable AD based on NINCDS criteria and symptoms for 1 year; MMSE 10-26; age > 50 years; mild to moderate AD; without other significant medical conditions Patients with stroke, tumor, subdural hematoma, hydrocephalus, or VaD Concurrent medications with cognitive properties such as anticholinergics, anticonvulsants, antidepressants, antipsychotics, anxiolytics, and stimulants were prohibited
Drugs Authors: Farlow et al. 58 Country: US and Canada Setting: 23 centers (21 US and 2 Canada) tacrine 20 to 80 mg/d 12 weeks 310
Alzheimer Year: 1992 Warner-Lambert Study design: RCT Sample size: 468
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
